for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Astrazeneca Says Lynparza Gets Broader U.S. Ovarian Cancer Approval

May 11 (Reuters) - AstraZeneca PLC:

* LYNPARZA GETS BROADER US OVARIAN CANCER APPROVAL

* LYNPARZA APPROVED IN US AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB FOR HRD-POSITIVE ADVANCED OVARIAN CANCER

* APPROVAL BY US FOOD AND DRUG ADMINISTRATION (FDA) WAS BASED ON A BIOMARKER SUBGROUP ANALYSIS OF PHASE III PAOLA-1 TRIAL

*

* PATIENTS TREATED WITH LYNPARZA & BEVACIZUMAB LIVED WITHOUT DISEASE PROGRESSION FOR 37.2 MONTHS VERSUS. 17.7 MONTHS MEDIAN FOR BEVACIZUMAB

* FOLLOWING THIS APPROVAL FOR LYNPARZA IN US, ASTRAZENECA WILL RECEIVE FROM MSD $100M IN COLLABORATION REVENUE

* LYNPARZA GETS BROADER US OVARIAN CANCER APPROVAL Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up